ALX Oncology (NASDAQ:ALXO) Sets New 52-Week High at $17.45

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report)'s share price hit a new 52-week high during trading on Monday . The company traded as high as $17.45 and last traded at $17.32, with a volume of 247131 shares trading hands. The stock had previously closed at $16.86.

Analyst Ratings Changes

A number of equities analysts have issued reports on ALXO shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of ALX Oncology in a report on Wednesday, April 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of ALX Oncology in a report on Friday, April 12th. Finally, Stifel Nicolaus reiterated a "hold" rating and issued a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, ALX Oncology presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.83.

ALX Oncology Price Performance

The company has a market capitalization of $846.50 million, a PE ratio of -4.51 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. The firm has a 50-day moving average of $13.65 and a 200 day moving average of $12.36.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last announced its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). As a group, research analysts anticipate that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the firm's stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the transaction, the insider now directly owns 628,359 shares of the company's stock, valued at $7,006,202.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Jaume Pons sold 20,000 shares of the firm's stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the transaction, the insider now owns 628,359 shares of the company's stock, valued at $7,006,202.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jason Lettmann acquired 4,400 shares of the firm's stock in a transaction dated Thursday, March 14th. The stock was bought at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the purchase, the chief executive officer now directly owns 171,620 shares of the company's stock, valued at $1,941,022.20. The disclosure for this purchase can be found here. Insiders own 50.30% of the company's stock.

Institutional Trading of ALX Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALXO. Vestal Point Capital LP bought a new stake in ALX Oncology during the 4th quarter valued at approximately $24,643,000. TD Asset Management Inc bought a new stake in ALX Oncology in the 4th quarter worth approximately $1,048,000. abrdn plc purchased a new stake in shares of ALX Oncology during the 4th quarter worth approximately $986,000. Hsbc Holdings PLC purchased a new stake in shares of ALX Oncology during the 3rd quarter worth approximately $168,000. Finally, Jump Financial LLC purchased a new stake in shares of ALX Oncology during the 4th quarter worth approximately $371,000. Institutional investors own 97.97% of the company's stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.